Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accounts Payables (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Accounts Payables data on record, last reported at $2.4 million in Q3 2023.

  • For Q3 2023, Accounts Payables rose 58.58% year-over-year to $2.4 million; the TTM value through Sep 2023 reached $2.4 million, up 58.58%, while the annual FY2022 figure was $2.7 million, 16.06% down from the prior year.
  • Accounts Payables reached $2.4 million in Q3 2023 per CGEM's latest filing, roughly flat from $2.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $9.7 million in Q4 2020 and bottomed at $1.5 million in Q2 2021.
  • Average Accounts Payables over 4 years is $3.4 million, with a median of $2.5 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: skyrocketed 105.23% in 2022, then tumbled 67.79% in 2023.
  • A 4-year view of Accounts Payables shows it stood at $9.7 million in 2020, then plummeted by 67.26% to $3.2 million in 2021, then dropped by 16.06% to $2.7 million in 2022, then decreased by 9.62% to $2.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $2.4 million in Q3 2023, $2.4 million in Q2 2023, and $2.0 million in Q1 2023.